Pharmaceutical compositions and methods for treating acute respiratory distress syndrome (ARDS) in coronavirus disease (COVID-19)
The present invention relates to a pharmaceutical composition for use in the treatment of acute respiratory distress syndrome, multi-terminal organ failure and survival in the event of severe life-threatening in a patient with coronavirus disease 2019 (COVID-19), the pharmaceutical composition comprising (a) Sensaquinine; (b) an antiviral therapy for SARS-CoV-2 infection (including ridecevir, ivermectin, chloroquine, hydroxychloroquine, azithromycin, tenofovir, emtricitabine, ritonavir, lopinavir, ASC09, favipiravir, danoprovir, an angiotensin converting enzyme inhibitor (ACEI), an angiotensin receptor blocker (ARB), recombinant human angiotensin converting enzyme 2 (rhACE2), Xiyanping, alpha-interferon, influenza enzyme (DAS181); an immunomodulatory and cell-targeted therapy system (e.g., EPA-FFA), nitric oxide, PUL-042, Pam2CSK4 acetate, a TLR2 agonist, a TLR6 agonist, and a TLR9 agonist), convalescent plasma, stem cells or exosomes thereof, immunomodulatory and cell-targeted therapy (e.g., ENT-FFA), toltrazumab, Slulimab, Acateninib, Pirelidipine, tradipitant, CD24Fc, Emulumab, Analastin, TJ003234, BLD-2660, blood purification system, EPA-FFA, PAL-042, Pam2CSK4 acetate, TLR2 agonist, TLR6 The preparation method comprises the following steps of: preparing an oxygen concentrator, an oxygen generator, T89, a compound salvia miltiorrhiza dropping pill, a plasminogen supplement, a plasminogen activator and arteplase; (c) budesonide, a fever reduction support therapy (e.g., acetaminophen or ibuprofen), a steroid (dexamethasone, prednisolone), an anticoagulant (aspirin, heparin, a non-heparin anticoagulant such as argatroban, bivalirudin, danaparin sodium, fondaparinux sodium, or a direct oral anticoagulant (DOAC)), or a pharmaceutically acceptable salt thereof. (d) an inhalation synthetic surfactant, an endotoxin antibody, interferon-beta-1a, IV prostaglandin E1, a neutrophil elastase inhibitor, nitric oxide, and (e) an excipient. A method for the preparation of a composition for the treatment of acute respiratory distress syndrome, multiterminal organ failure and shock symptoms caused by coronavirus infections, in particular SARS-CoV-2, MERS-CoV and SARS-CoV, using a compound of Sensaquinine or an analog thereof, the mechanism is to reduce pulmonary edema, improve the ratio of arterial blood oxygen partial pressure to inhalation oxygen fraction (PaO2/FiO2 or SpO2/FiO2), oxyhemoglobin saturation (SpO2), normalize respiratory rate, reduce lung infiltration, improve ARDS score, MODS, level classification of COVID-19, and better blood flow and tissue oxygenation..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 23. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
GULATI ANIL [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-23, Last update posted on www.tib.eu: 2024-04-01, Last updated: 2024-04-09 |
|---|
| Patentnummer: |
CN117440812 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA002578492 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA002578492 | ||
| 003 | DE-627 | ||
| 005 | 20240409142315.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA002578492 | ||
| 035 | |a (EPA)CN117440812 | ||
| 035 | |a (EPA)83999346 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a GULATI ANIL |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmaceutical compositions and methods for treating acute respiratory distress syndrome (ARDS) in coronavirus disease (COVID-19) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-23, Last update posted on www.tib.eu: 2024-04-01, Last updated: 2024-04-09 | ||
| 520 | |a The present invention relates to a pharmaceutical composition for use in the treatment of acute respiratory distress syndrome, multi-terminal organ failure and survival in the event of severe life-threatening in a patient with coronavirus disease 2019 (COVID-19), the pharmaceutical composition comprising (a) Sensaquinine; (b) an antiviral therapy for SARS-CoV-2 infection (including ridecevir, ivermectin, chloroquine, hydroxychloroquine, azithromycin, tenofovir, emtricitabine, ritonavir, lopinavir, ASC09, favipiravir, danoprovir, an angiotensin converting enzyme inhibitor (ACEI), an angiotensin receptor blocker (ARB), recombinant human angiotensin converting enzyme 2 (rhACE2), Xiyanping, alpha-interferon, influenza enzyme (DAS181); an immunomodulatory and cell-targeted therapy system (e.g., EPA-FFA), nitric oxide, PUL-042, Pam2CSK4 acetate, a TLR2 agonist, a TLR6 agonist, and a TLR9 agonist), convalescent plasma, stem cells or exosomes thereof, immunomodulatory and cell-targeted therapy (e.g., ENT-FFA), toltrazumab, Slulimab, Acateninib, Pirelidipine, tradipitant, CD24Fc, Emulumab, Analastin, TJ003234, BLD-2660, blood purification system, EPA-FFA, PAL-042, Pam2CSK4 acetate, TLR2 agonist, TLR6 The preparation method comprises the following steps of: preparing an oxygen concentrator, an oxygen generator, T89, a compound salvia miltiorrhiza dropping pill, a plasminogen supplement, a plasminogen activator and arteplase; (c) budesonide, a fever reduction support therapy (e.g., acetaminophen or ibuprofen), a steroid (dexamethasone, prednisolone), an anticoagulant (aspirin, heparin, a non-heparin anticoagulant such as argatroban, bivalirudin, danaparin sodium, fondaparinux sodium, or a direct oral anticoagulant (DOAC)), or a pharmaceutically acceptable salt thereof. (d) an inhalation synthetic surfactant, an endotoxin antibody, interferon-beta-1a, IV prostaglandin E1, a neutrophil elastase inhibitor, nitric oxide, and (e) an excipient. A method for the preparation of a composition for the treatment of acute respiratory distress syndrome, multiterminal organ failure and shock symptoms caused by coronavirus infections, in particular SARS-CoV-2, MERS-CoV and SARS-CoV, using a compound of Sensaquinine or an analog thereof, the mechanism is to reduce pulmonary edema, improve the ratio of arterial blood oxygen partial pressure to inhalation oxygen fraction (PaO2/FiO2 or SpO2/FiO2), oxyhemoglobin saturation (SpO2), normalize respiratory rate, reduce lung infiltration, improve ARDS score, MODS, level classification of COVID-19, and better blood flow and tissue oxygenation. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 23. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/83999346/publication/CN117440812A1?q=CN117440812 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 01 | ||